Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,052
archived clinical trials in
Nephrology

Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy
Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial
Status: Enrolling
Updated:  3/10/2015
USC Institute of Urology
mi
from
Los Angeles, CA
Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy
Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial
Status: Enrolling
Updated: 3/10/2015
USC Institute of Urology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy
Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial
Status: Enrolling
Updated:  3/10/2015
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy
Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial
Status: Enrolling
Updated: 3/10/2015
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated:  4/28/2015
Clinical Research Facility
mi
from
Birmingham, AL
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated: 4/28/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated:  4/28/2015
Clinical Research Facility
mi
from
Boston, MA
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated: 4/28/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated:  4/28/2015
Clinical Research Facility
mi
from
Royal Oak, MI
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated: 4/28/2015
Clinical Research Facility
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated:  4/28/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated: 4/28/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated:  4/28/2015
Clinical Research Facility
mi
from
Somers Point, NJ
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)
Status: Enrolling
Updated: 4/28/2015
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation
Status: Enrolling
Updated:  7/29/2015
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
mi
from
New York, NY
Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation
Status: Enrolling
Updated: 7/29/2015
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Baltimore, MD
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Tucson, AZ
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Orange, CA
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Miami, FL
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Savannah, GA
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Chicago, IL
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Durham, NC
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Providence, RI
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Memphis, TN
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
San Antonio, TX
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Madison, WI
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated:  7/29/2015
mi
from
Adrogué,
Gadobutrol Enhanced MRA of the Renal Arteries
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status: Enrolling
Updated: 7/29/2015
mi
from
Adrogué,
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
San Francisco, CA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Stanford, CA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Springfield, IL
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Bethesda, MD
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Boston, MA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Detroit, MI
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Rochester, MN
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
St Louis, MO
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
New York, NY
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
New York, NY
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
New York, NY
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Rosedale, NY
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Rosedale, NY
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Houston, TX
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated:  8/12/2015
Investigational Site Number 4104
mi
from
Porto Alegre,
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status: Enrolling
Updated: 8/12/2015
Investigational Site Number 4104
mi
from
Porto Alegre,
Click here to add this to my saved trials
Renal Artery Contrast-Free Trial
Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography
Status: Enrolling
Updated:  8/24/2015
Central Coast Cardiolgy
mi
from
Salinas, CA
Renal Artery Contrast-Free Trial
Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography
Status: Enrolling
Updated: 8/24/2015
Central Coast Cardiolgy
mi
from
Salinas, CA
Click here to add this to my saved trials
Bariatric Surgery and the Kidney
Study of Renal Parameters After Bariatric Surgical Weight Loss
Status: Enrolling
Updated:  8/26/2015
University Hospital
mi
from
Indianapolis, IN
Bariatric Surgery and the Kidney
Study of Renal Parameters After Bariatric Surgical Weight Loss
Status: Enrolling
Updated: 8/26/2015
University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5
Status: Enrolling
Updated:  9/3/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5
Status: Enrolling
Updated: 9/3/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
Status: Enrolling
Updated:  9/18/2015
University of Toledo
mi
from
Toledo, OH
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
Status: Enrolling
Updated: 9/18/2015
University of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials